Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Cancer|Melanoma|Solid Tumor|Squamous Cell Carcinoma of Head and Neck|Breast Cancer|Advanced Solid Tumor|Triple Negative Breast Cancer|Colorectal Carcinoma|Non-melanoma Skin Cancer|Liver Metastases
Interventions: BIOLOGICAL: ONCR-177|BIOLOGICAL: pembrolizumab
Sponsor: Oncorus, Inc.
Collaborators: Merck Sharp & Dohme LLC